Personalized medicine in oncology: The future is now

Nature Reviews Drug Discovery

Volumn 9, Issue 5, 2010, Pages 363-366

  Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CLEARANCE; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG TARGETING; GENE MUTATION; GENETIC POLYMORPHISM; GLIOMA; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HEALTH CARE COSTS; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951778977     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3181     Document Type: Review

References (36)

1. Peppercorn, J., Perou, C. M. & Carey, L. A. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 26, 1-10 (2008).
2. van de Vijver, M. J. et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
3. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
4. Potti, A. et al. A genomic strategy to refine prognosis in early stage non small cell lung cancer. N. Engl. J. Med. 355, 570-580 (2006).
5. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
6. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
7. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
8. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in gliobalstoma. N. Engl. J. Med. 352, 997-1003 (2005).
9. O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
10. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
11. Paik, S. et al. A multi-gene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
12. Hayes, D. F. et al. Her2 and response to paclitaxel in node positive breast cancer. N. Engl. J. Med. 357, 1496-1506 (2007).
13. Olaussen, K. A. et al. DNA repair by ERCC1 in non small cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991 (2006).
14. Schuster, S. J. et al. Idiotype vaccine therapy (Biovax ID) in follicular lymphoma in first complete remission: phase III clinical trial results. J. Clin. Oncol. 27 (Jun 20 Suppl.), 2 (2009).
15. Innocenti, F. et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27, 2604-2614 (2009).
16. Dezentjé, V. O., Guchelaar, H.-J., Nortier, J. W., van de Velde, C. J. & Gelderblom, H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin. Cancer Res. 15, 15-21 (2009).
17. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007).
18. Kris, M. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor tyrosine kinase, in symptomatic patients with non small cell lung cancer. JAMA 290, 2149-2158 (2003).
19. Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial\INTACT 1. J. Clin. Oncol. 22, 777-784 (2004). (Pubitemid 41103588)
20. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial\INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
21. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
22. Kobayashi, S. et al. EGFR mutation and resistance of non small cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005). (Pubitemid 40271173)
23. Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non small cell lung cancer. Clin. Cancer Res. 14, 2895-2899 (2008).
24. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
25. O'Reilly, K. E. et al. mTor inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 66, 1500-1508 (2006).
26. Mandrekar, S. J. & Sargent, D. J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 27, 4027-4034 (2009).
27. Shepherd, F. A. et al. Erlotinib in previously treated non small cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
28. Bradbury, P. A. et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J. Natl Cancer Inst. 102, 1-9 (2010).
29. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
30. Di Fiore, F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. B r. J. Cancer 96, 1166-1169 (2007).
31. Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008).
32. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
33. Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
34. Shankaran, V., Bentrem, D. J., Mulcahy, M. F., Bennett, C. L. & Benson, A. B. III. Economic implications of kras testing in metastatic colorectal cancer (mCRC). American Association of Clincal Oncology website [online], http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view&confID=63&abstractID=10759 (2009).
35. Mittmann, N. et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J. Natl Cancer Inst. 101, 1182-1192 (2009).
36. Sartore-Bianchi, A. et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLOS One 4, e7287 (2009).